Confidential — Accredited Investors Only
A vertically integrated venture printing human tissue from a patient's own stem cells — and developing Kiros, a new class of AI built to be decentralized, open, and aligned.
Request investor accessTwo pillars, one mission
Proprietary 3D bioprinting of human tissue and organs using a patient's own stem cells. Built around methodologies developed in-house and now entering the regulatory pathway.
Kiros is the intelligence layer beneath the printers and the R&D engine that compounds every experiment we run.
Structure
A standard equity vehicle holding the IP, regulatory work, and manufacturing operations. Investors hold equity in the operating entity.
A separate decentralized autonomous organization stewards the governance of Kiros. Designed so that the AI's future cannot be captured by any single party, including us.
The Round
Allocations and terms are shared privately with qualified investors.
Investor access
Enter your details and select a call date below.
Thank you, there. Your requested time is:
I'll personally email you shortly to confirm and share dial-in details.
Legal Notice
This website and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy any security. Any offer or solicitation will be made solely by means of confidential offering documents and only to qualified persons in jurisdictions where such offer or solicitation is lawful.
Securities referenced have not been registered under the U.S. Securities Act of 1933, as amended, or any state securities laws. They may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any offering will be conducted in reliance on exemptions thereunder, including Regulation D, and will be available only to accredited investors as defined in Rule 501.
Investments in early-stage ventures are speculative and involve a high degree of risk, including the potential loss of the entire investment. Past performance is not indicative of future results. Forward-looking statements reflect current expectations and are subject to risks and uncertainties; actual results may differ materially. Information herein is confidential and may not be reproduced or distributed without consent.
No regulatory authority has approved or disapproved of any securities or passed upon the adequacy of any disclosure. The bioprinting platform described is in development and has not received regulatory clearance for clinical use.